Skip to main content

Dr. Andy Y. Lee, MD

Heart Failure & Transplant Cardiology (Advanced Heart Failure and Transplant Cardiology Physician)

  • Medicare participating

At a glance

Years since graduation
7
In the NPI registry since
2013
Medicare patients seen, 2024
1,656

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2013Registered with an NPI (national billing number; not a license date)

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Advanced Heart Failure and Transplant Cardiology Physician primary
    CA license A135643
  • Cardiovascular Disease Physician
    CA license A135643
  • Internal Medicine Physician
    CA license A135643

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Heart Failure & Transplant Cardiology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
1,656
Services billed
2,825
Patients’ average age
75
Most frequent Medicare services, 2023
ServiceTimesPatients
Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only716624
Ultrasound of heart with color-depicted blood flow, rate, direction and valve function321318
Established patient office or other outpatient visit, 30-39 minutes255157
Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report107107
Established patient office or other outpatient visit, 20-29 minutes9775
Ultrasound of heart with color-depicted blood flow, rate and valve function9291
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes9030
Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician6767
Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician6363
Ultrasound of heart blood flow, valves and chambers5656

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 6 companies reported 13 payments worth $1,445 in total to this clinician.

By type
Food and Beverage$749
Travel and Lodging$696

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Nov 26, 2025Abbott Laboratories
Nov 26, 2025
Travel and Lodging
CARDIOMEMS · Structural Heart · travel to San Francisco, CA · in-kind
$597
Nov 26, 2025Abbott Laboratories
Nov 26, 2025
Travel and Lodging
CARDIOMEMS · Structural Heart · travel to San Francisco, CA · in-kind
$90.06
Nov 26, 2025Abbott Laboratories
Nov 26, 2025
Travel and Lodging
CARDIOMEMS · Structural Heart · travel to San Francisco, CA · in-kind
$9.02

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in California →

Industry-funded research

Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $90,389 in research payments for these studies, mostly to the institutions running them.

  • A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly…
    Amgen Inc.
  • A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
    Eli Lilly and Company · Active, not recruiting · NCT05556512
  • A multi-center, randomized, double-blind placebo-controlled and open-label active-controlled, parallel-group, 24-week proof of concept and dose-finding study to evaluate efficacy, safety, and tolerability of XXB750 in…
    Novartis Pharmaceuticals Corporation

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Heart Failure & Transplant Cardiology clinicians in Newport Beach

Sources

NPI registry (CMS NPPES, November 2026; record last updated October 28, 2026), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1013250463. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.